Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
25. Oktober 2024 17:34 ET
|
Tevogen Bio Inc
WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
21. Oktober 2024 15:58 ET
|
Tevogen Bio Inc
Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen Bio's Oncology therapeutic area projections of $1 billion in the launch year and $10–$14 billion...
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
24. September 2024 11:09 ET
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
04. September 2024 09:15 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for...
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
04. September 2024 08:30 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The emergence of SARS-CoV-2, which triggered the COVID-19 pandemic with overall is widely regarded as the...
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
22. August 2024 14:15 ET
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27. Juni 2024 10:30 ET
|
BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
27. Juni 2024 10:30 ET
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
06. Juni 2024 15:52 ET
|
Tevogen Bio Inc
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate Update
14. November 2023 16:05 ET
|
Icosavax, Inc.
- Reported positive twelve-month durability data and initial proof-of-concept for revaccination with IVX-121 against RSV - - IVX-A12 (RSV+hMPV) Phase 2 topline interim data expected by end of 2023...